Research Article
A Single-Center 18-Year Series of 73 Cases of Metaplastic Carcinoma of the Breast
Table 1
Characteristics of the patients (n = 73).
| | Age (years) | | | ≤55 | 26 (35.6%) | | >55 | 47 (64.4%) | | Median (range) | 61.5 (32–96) | | Menopausal | 56 (76.7%) | | Subtype | | | Adenosquamous, low-grade | 1 (1.4%) | | Fibromatosis-like | 1 (1.4%) | | Spindle cell | 11 (15.1%) | | Squamous cell | 13 (17.8%) | | Heterologous mesenchymal cell differentiation | 18 (24.7%) | | Mixed | 29 (39.7%) | | Clinical stage | | | cT | | | cT1 | 16 (21.9%) | | cT2 | 26 (35.9%) | | cT3 | 16 (21.9%) | | cT4 | 7 (9.6%) | | Unknown | 8 (11.0%) | | cN | | | cNx | 6 (8.2%) | | cN0 | 55 (75.3%) | | cN1 | 10 (13.7%) | | cN2 | 2 (2.7%) | | cN3 | 0 | | cM | | | cMx | 3 (4.1%) | | cM0 | 65 (89.0%) | | cM1 | 5 (6.9%) | | Nuclear grade | | | G1 | 1 (1.4%) | | G2 | 7 (9.6%) | | G3 | 55 (75.3%) | | Unknown | 10 (13.7%) | | Lymphovascular invasion | 13 (17.8%) | | HER2—positive | 3 (4.1%) | | HER2—unknown | 4 (5.5%) | | Combined receptor profile | | | HR+, HER2+ | 1 (1.4%) | | HR−, HER2− | 58 (79.5%) | | HR+, HER2− | 8 (11.0%) | | HR−, HER2+ | 2 (2.7%) | | HR+, HER2? | 3 (4.1%) | | HR−, HER2? | 1 (1.4%) | | Surgery | | | Breast-conserving surgery | 36 (49.3%) | | Mastectomy | 37 (50.7%) | | Axillary surgery | | | Sentinel lymph node biopsy | 39 (53.4%) | | Axillary dissection | 26 (35.6%) | | None | 8 (11.0%) | | Radiation therapy | 53 (72.6%) | | Treatments | | | Breast-conserving surgery, RT | 33 (45.2%) | | Breast-conserving surgery, no RT | 3 (4.1%) | | Mastectomy, RT | 20 (27.4%) | | Mastectomy, no RT | 17 (23.3%) | | Systemic therapy | 51 (69.9%) | | Chemotherapy | 42 (57.5%) | | Chemotherapy and hormonal therapy | 7 (9.6%) | | Hormonal therapy | 2 (2.7%) | | Systemic chemotherapy (n = 49) | | | Cyclophosphamide and doxorubicin | 11 (22.5%) | | Cyclophosphamide and epirubicin | 1 (2.0%) | | Docetaxel | 1 (2.0%) | | 5-fluorouracil, doxorubicin, and cyclophosphamide | 1 (2.0%) | | 5-fluorouracil, doxorubicin, cyclophosphamide, and taxane | 8 (16.3%) | | Cyclophosphamide, doxorubicin, and taxane | 5 (10.2%) | | Carboplatin and taxane | 2 (4.1%) | | Carboplatin and cyclophosphamide | 8 (16.3%) | | Docetaxel, doxorubicin, and cyclophosphamide | 1 (2.0%) | | Clinical trial | 4 (8.2%) | | Unknown | 7 (14.3%) | | Trastuzumab | 2 (2.7%) | | Chemotherapy | 49 (49.7%) | | Adjuvant | 36 (49.3%) | | Neoadjuvant | 9 (12.4%) | | Metastatic | 4 (5.5%) | | Pathological stage pT | | | pTx | 1 (1.4%) | | pT0 | 1 (1.4%) | | pT1 | 16 (21.9%) | | pT2 | 42 (57.5%) | | pT3 | 9 (12.3%) | | pT4 | 4 (5.5%) | | pN | | | pNx | 8 (11.0%) | | pN0 | 48 (65.8%) | | pN1 | 9 (12.3%) | | pN2 | 4 (5.5%) | | pN3 | 4 (5.5%) |
|
|
HR: hormonal receptor; LN: lymph node; RT: radiotherapy.
|
